Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Other Non-Current Assets (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Other Non-Current Assets for 9 consecutive years, with $107000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $107000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $107000.0, a N/A change, with the full-year FY2025 number at $107000.0, changed N/A from a year prior.
  • Other Non-Current Assets was $107000.0 for Q4 2025 at Crescent Biopharma, down from $1.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.2 million in Q1 2022 to a low of $50000.0 in Q1 2023.
  • A 5-year average of $673169.3 and a median of $173222.0 in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 2882.81% in 2021, then plummeted 97.75% in 2023.
  • Crescent Biopharma's Other Non-Current Assets stood at $52320.0 in 2021, then soared by 463.28% to $294710.0 in 2022, then crashed by 47.69% to $154176.0 in 2023, then crashed by 66.06% to $52320.0 in 2024, then surged by 104.51% to $107000.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Other Non-Current Assets are $107000.0 (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025).